which said that Pfizer's revenues are now "higher than the GDP of most countries", and that the company is " ripping off public health systems with an eye-watering mark-up." The comments came as ...

Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

A look at the shareholders of Pfizer Inc. (NYSE:PFE) can tell us which group is most powerful. The group holding the most number of shares in the company, around 68% to be precise, is institutions.

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Risinger now forecasts that the biopharmaceutical company will post earnings per share of $0.54 for the quarter, down from their previous estimate of $0.58. The consensus estimate for Pfizer’s ...

TYSON 2.0 Eye Drops will be available in smoke shops nationwide and will debut at the CHAMPS Trade Show in Las Vegas, one of the premier gatherings for industry professionals. Wholesale and ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...

In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...

The acquisition will help the company expand its reach and presence with its existing merchant partners. While the Hyderabad-based company has managed to secure a foothold on the corporate side ...